SCHEMBL20904110

SCHEMBL20904110

CC(=O)CCCC(=O)N1CCNCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.52
NPC1 O15118 1/20 0.48
GNAI3 P08754 5/20 0.46
GNAI1 P63096 5/20 0.46
GNAO1 P09471 4/20 0.46
ITGB3 P05106 2/20 0.46
ITGA2B P08514 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
GAA P10253 1/20 0.41
GLA P06280 1/20 0.41
CA2 P00918 2/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA9 Q16790 1/20 0.41
DDB1 Q16531 1/20 0.40
CRBN Q96SW2 1/20 0.40
CHKA P35790 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23813810 0.88 CA2 (0.43) ATMNPC1GNAI3GNAI1GNAO1
SCHEMBL10337915 0.84 GNAI3 (0.56) ATMNPC1GNAI3GNAI1GNAO1
SCHEMBL16756662 0.84 GNAI3 (0.56) ATMNPC1GNAI3GNAI1GNAO1
SCHEMBL9415827 0.84 GNAI3 (0.56) ATMNPC1GNAI3GNAI1GNAO1
SCHEMBL9415769 0.84 GNAI3 (0.56) ATMNPC1GNAI3GNAI1GNAO1
SCHEMBL2998705 0.82 L3MBTL1 (0.60) ATMNPC1GNAI3GNAI1GNAO1
SCHEMBL29649523 0.82 ITGB3 (0.64) ATMNPC1GNAI3GNAI1GNAO1
SCHEMBL25867742 0.82 ATM (0.78) ATMNPC1L3MBTL1MEN1KMT2A
SCHEMBL1073791 0.81 L3MBTL1 (0.69) ATMNPC1GNAI3GNAI1GNAO1
SCHEMBL6043280 0.80 ATM (0.50) ATMNPC1GNAI3GNAI1GNAO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210228615-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2021-07-29 US disclosed
US-20200157545-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF WAVE LIFE SCIENCES LTD. (SG) 2020-05-21 US disclosed
WO-2019075357-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2019-04-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210228615-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF SMN1; SMN2, RBM17, RBM22 ATM 2102/4885NPC1 4454/4885GNAI3 2130/4885
US-20200157545-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF RNASE1, RNASEH1, RNASEL ATM 4293/4885NPC1 1153/4885GNAI3 1256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.